GlassScriptPhysician profile
John M Demicco
NPI 1285632125
$30,921.40
in general payments reported to CMS, 2019-2025
75 companies · $5,969 in 2025
The $5,969 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,864 · 2020: $3,182 · 2021: $3,771 · 2022: $4,079 · 2023: $5,153 · 2024: $4,903 · 2025: $5,969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Education: $440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,585.36 |
| Education | $440.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,532.24 | 2019-2025 | Rinvoq, Vraylar, Skyrizi |
| Amgen INC. | $3,758.35 | 2019-2025 | Krystexxa, Enbrel, Tavneos |
| Mallinckrodt Hospital Products INC. | $1,800.86 | 2020-2025 | Acthar |
| Janssen Biotech, INC. | $1,758.75 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Astrazeneca Pharmaceuticals LP | $1,701.29 | 2019-2025 | Saphnelo, Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $1,701.20 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,679.95 | 2019-2025 | Benlysta, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $1,311.92 | 2019-2025 | |
| Novo Nordisk INC | $1,151.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Horizon Therapeutics Plc | $1,093.87 | 2019-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $1,004.78 | 2022-2025 | Purified Cortrophin Gel |
| Axsome Therapeutics, INC. | $998.01 | 2022-2025 | Sunosi |
| Sandoz INC. | $788.52 | 2023-2025 | Hyrimoz, Jubbonti |
| Ucb, INC. | $667.17 | 2019-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $538.79 | 2019-2025 |
Show all 75 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Demicco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.